Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v18-EN Version v12-EN
Language English English
Date Updated 2017-12-04 2017-07-25
Drug Identification Number 02387468 02387468
Brand name LABETALOL HYDROCHLORIDE INJECTION, USP LABETALOL HYDROCHLORIDE INJECTION, USP
Common or Proper name LABETALOL HYDROCHLORIDE INJECTION, USP LABETALOL HYDROCHLORIDE INJECTION, USP
Company Name MYLAN PHARMACEUTICALS ULC MYLAN PHARMACEUTICALS ULC
Ingredients LABETALOL HYDROCHLORIDE LABETALOL HYDROCHLORIDE
Strength(s) 5MG 5MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 20ML 1VL 20ML 1VL
ATC code C07AG C07AG
ATC description BETA BLOCKING AGENTS BETA BLOCKING AGENTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2017-08-03 2017-08-03
Actual start date 2017-07-31
Estimated end date 2018-02-16 2017-10-13
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments